Systemic adverse effects of topical ocular treatments.
Some eyedrops, gels or ointments may cause adverse effects as serious as those observed with systemic therapies. Because of their relatively poor penetration into eye tissue, ophthalmic drugs usually contain high concentrations of their active ingredient. Asking patients about these drugs to prevent interactions is useful when prescribing a new systemic treatment. Conversely, it is advisable to ask about ophthalmic drugs during the etiological investigation of possible iatrogenic effects.
Labetoulle
Marc
M
Service d'ophtalmologie, CHU de Bicêtre, Le Kremlin-Bicêtre (94), Assistance Publique--Hôpitaux de Paris. marc.labetoulle@bct.ap-hop-paris.fr
Frau
Eric
E
Le Jeunne
Claire
C
D000287:Administration, Topical; D000367:Age Factors; D000368:Aged; D001682:Biological Availability; D002648:Child; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D005123:Eye / Q000187:drug effects* / Q000378:metabolism; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D016330:Frail Elderly; D005782:Gels; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007049:Iatrogenic Disease; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology; D009824:Ointments; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology; D012307:Risk Factors
D005782:Gels; D009184:Mydriatics; D009824:Ointments; D009883:Ophthalmic Solutions